Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1984; 4:621-624
© 1984 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chow, M.
Right arrow Articles by Atkinson, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chow, M.
Right arrow Articles by Atkinson, A., Jr

Torsade de pointes induced by N-acetylprocainamide

MJ Chow, AA Piergies, DJ Bowsher, JJ Murphy, W Kushner, TI Ruo, A Asada, JV Talano, and AJ Atkinson Jr

N-Acetylprocainamide (NAPA), a class III antiarrhythmic drug, caused torsade de pointes in a 72 year old woman who had this arrhythmia on two previous occasions while being treated with quinidine and disopyramide. Initial evaluation with an intravenous infusion of NAPA indicated a favorable antiarrhythmic response. The QTC interval was prolonged, but the 2.4 ms/microgram per ml incremental QTC interval lengthening caused by NAPA was not greater than usual. During subsequent oral therapy with NAPA, torsade de pointes developed at plasma levels of this drug that appeared to be well tolerated during the initial evaluation.


This article has been cited by other articles:


Home page
Eur Heart J SupplHome page
J.L. Bauman
The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K93 - K100.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt
Experimental models of torsade de pointes
Cardiovasc Res, July 1, 1998; 39(1): 178 - 193.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. T. DOMOTO, W. W. BROWN, and P. BRUGGENSMITH
Removal of Toxic Levels of N-Acetylprocainamide with Continuous Arteriovenous Hemofiltration or Continuous Arteriovenous Hemodiafiltration
Ann Intern Med, April 1, 1987; 106(4): 550 - 552.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
S. C. BORKAN
Hemoperfusion for N-Acetylprocainamide Intoxication
Ann Intern Med, December 1, 1986; 105(6): 965 - 966.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
G. L. BRADEN, J. P. FITZGIBBONS, M. J. GERMAIN, and H. M. LEDEWITZ
Hemoperfusion for Treatment of N-Acetylprocainamide Intoxication
Ann Intern Med, July 1, 1986; 105(1): 64 - 65.
[Abstract] [PDF]


Home page
ANN INTERN MEDHome page
K. P. V. NGUYEN, G. THOMSEN, B. LIEM, C. D. SWERDLOW, and M. R. FRANZ
N-Acetylprocainamide, Torsades de Pointes, and Hemodialysis
Ann Intern Med, February 1, 1986; 104(2): 283 - 284.
[Abstract] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement